Double-barreled cell therapy takes aim at hard-to-treat myeloma
NCT ID NCT07003568
First seen Nov 19, 2025 · Last updated May 17, 2026 · Updated 19 times
Summary
This early-stage study tests a new treatment for people with advanced multiple myeloma that has spread outside the bones. The therapy uses a patient's own immune cells, modified to attack two cancer targets (BCMA and GPRC5D) at once. The main goal is to check safety in 18 adults, with a focus on side effects in the first month after treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai Liquan Hospital
RECRUITINGShanghai, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.